DOCSLIB.ORG

NULOJIX, Through the Centralised Procedure Falling Within the Article 3(1) and Point 1 of Annex of Regulation (EC) No 726/2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NULOJIX, Through the Centralised Procedure Falling Within the Article 3(1) and Point 1 of Annex of Regulation (EC) No 726/2004 Assessment report NULOJIX International Nonproprietary Name: Belatacept Procedure No. EMEA/H/C/2098 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 4 1.1. Submission of the dossier.................................................................................... 4 1.2. Steps taken for the assessment of the product ....................................................... 4 2. Scientific discussion ................................................................................ 5 2.1. Introduction ...................................................................................................... 5 2.2. Quality aspects .................................................................................................. 7 2.3. Non-clinical aspects .......................................................................................... 12 Methods of analysis ................................................................................................ 17 Absorption............................................................................................................. 18 Distribution............................................................................................................ 18 Metabolism ............................................................................................................ 18 Excretion............................................................................................................... 18 Pharmacokinetic drug interactions............................................................................. 18 Single dose toxicity................................................................................................. 19 Repeat-dose toxicity ............................................................................................... 19 Genotoxicity .......................................................................................................... 22 Carcinogenicity....................................................................................................... 22 Local tolerance....................................................................................................... 23 Other toxicity studies .............................................................................................. 24 2.4. Clinical aspects ................................................................................................ 29 2.5. Clinical efficacy ................................................................................................ 38 2.6. Clinical safety .................................................................................................. 63 2.7. Pharmacovigilance............................................................................................ 76 2.8. Benefit-Risk Balance......................................................................................... 81 2.9. Recommendation ............................................................................................. 85 Assessment report Nulojix Page 2/85 List of abbreviations ADR adverse drug reaction AR acute rejection AUC area under the concentration-time curve (over one dosing interval) BMS Bristol-Myers Squibb CAN chronic allograft nephropathy CIT cold ischemia time CKD chronic kidney disease Cmax maximum concentration Cmin trough serum concentration CMV cytomegalovirus CNI calcineurin inhibitor CRF case report form CsA cyclosporine A CTS Collaborative Transplant Study CV cardiovascular CYP450 cytochrome P450 DGF delayed graft function DMC Data Monitoring Committee EBV Epstein Barr virus ECD extended criteria donor ESRD end-stage renal disease GFR glomerular filtration rate HDL high density lipoprotein HLA human leukocyte antigen IL Interleukin ITT intent-to-treat LDL low density lipoprotein LDT lymphocyte depleting therapy LI less intensive (belatacept regimen) MDRD Modification of Diet in Renal Disease (i e Levey formula) MedDRA Medical Dictionary for Regulatory Activities MI more intensive (belatacept regimen) MMF mycophenolate mofetil MPA mycophenolic acid NKF National Kidney Foundation NODM new onset diabetes mellitus PMA phorbol myristate acetate PML progressive multifocal leukoencephalopathy PRA panel reactive antibodies PTLD post-transplant lymphoproliferative disorder SCD standard criteria donors SCr serum creatinine SD standard deviation SRL sirolimus TB tuberculosis UNOS United Network of Organ Sharing USRDS United States Renal Data System UTI urinary tract infection Assessment report Nulojix Page 3/85 1. Background information on the procedure 1.1. Submission of the dossier The applicant Bristol-Myers Squibb Pharma EEIG submitted on 03 February 2010 an application for Marketing Authorisation to the European Medicines Agency (EMA) for NULOJIX, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 23 April 2009. The applicant applied for the following indication: prophylaxis of graft failure and dysfunction in adult patients receiving a renal transplant. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC. The application submitted is composed of administrative information, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/99/2008 for the following condition: Renal transplantation on the agreement of a paediatric investigation plan (PIP) with a deferral. The PIP is not yet completed. Information relating to orphan market exclusivity Similarity Not applicable. Market Exclusivity Not applicable. Scientific Advice: The applicant received Scientific Advice from the CHMP on 18 February 2005. The Scientific Advice pertained to non-clinical and clinical aspects of the dossier. Licensing status A new application was filed in the following countries: USA The product was not licensed in any country at the time of submission of the application. 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Assessment report Nulojix Page 4/85 Rapporteur: Dr. Tomas Salmonson (SE) Co-Rapporteur: Dr. Romaldas Mačiulaitis (LT) The application was received by the EMA on 03 February 2010. The procedure started on 24 February 2010. The Rapporteur's first Assessment Report was circulated to all CHMP members on 12 May 2010. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 15 May 2010. During the meeting in June 2010, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 24 June 2010. The applicant submitted the responses to the CHMP consolidated List of Questions on 14 December 2010. The summary reports of the GMP inspection carried out at the following sites: BioReliance Corporation, 9900 Blackwell Road, Rockville, Maryland – USA, Bioreliance Corporation - 9630 Medical Center Drive - Rockville, Maryland – USA; Bioreliance Corporation, 14920 Broschart Road, Rockville, MD, USA between 20th – 24th September 2010; and C Beckman Coulter Genomics100 Perimeter Park Drive 27560 Morrisville, NC USA between 30th September – 1st October 2010 were issued on 21 January 2011 and 14 January 2011 respectively. A GCP inspection was carried out at two investigator sites in Argentina (20-24 September 2010 and 27-30 September 2010) in relation to the conduct of the two trials IM103008 and IM 103027. The final integrated inspection report was issued on 25 October 2010. The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of Questions to all CHMP members on 28 January 2011. During the CHMP meeting on 14-17 February 2011, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant. The applicant submitted the responses to the CHMP List of Outstanding Issues on 14 March 2011. During the meeting in April 2011, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Nulojix on 14 April 2011. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 13 April 2011. 2. Scientific discussion 2.1. Introduction Problem statement End stage renal disease (ESRD) is a global health issue with an incidence that is growing at an annual rate of 8%, outpacing the annual population growth rate of 1.3%. Renal transplantation is the preferred treatment for ESRD because it confers improved survival and quality of life over dialysis. After transplantation, recipients require lifelong immunosuppression to suppress the alloimmune response and maintain a functioning graft. Therapeutic advances, such as the calcineurin inhibitors, CNI, (ciclosporin, CsA, and tacrolimus) are the current mainstays of immunosuppressive
Load more

Recommended publications
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • Project Protocol
    CADTH Health Technology Assessment June 2016 (Update Drugs for the management of rheumatoid May 2017) arthritis: clinical evaluation – project protocol PROSPERO Registration Number: CRD42016041498 1 Cite as: Drugs for the management of rheumatoid arthritis: clinical evaluation – project protocol. Ottawa: CADTH; 2016 Jun; updated 2017 April. This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH) in collaboration with the Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (DSEN). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and its creation was guided by expert input and advice throughout its preparation. The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.
    [Show full text]
  • Australian Public Assessment Report for Abatacept (Rch)
    Australian Public Assessment Report for Abatacept (rch) Proprietary Product Name: Orencia Sponsor: Bristol-Myers Squibb Australia Pty Ltd June 2011 About the Therapeutic Goods Administration (TGA) · The TGA is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. · TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • A PILOT RANDOMIZED CONTROLLED TRIAL of DE NOVO BELATACEPT-BASED IMMUNOSUPPRESSION in LUNG TRANSPLANTATION Howard J. Huang, MD Ra
    A PILOT RANDOMIZED CONTROLLED TRIAL OF DE NOVO BELATACEPT-BASED IMMUNOSUPPRESSION IN LUNG TRANSPLANTATION Howard J. Huang, MD Ramsey R. Hachem, MD Study ID: IM103-387 Draft: v 6.0 Date: 8 December 2017 ! 1 TABLE OF CONTENTS Section Page 1. List of Abbreviations 3 2. Protocol Summary 4 3. Study Schematic 4 4. Key Roles 5 5. Introduction 6 6. Objectives and Purpose 7 7. Study Design and Endpoints 7 8. Study Enrollment 8 9. Study Agent 11 10. Study Procedures and Schedule 11 11. Safety Considerations 13 12. Statistical Considerations 18 13. References 19 ! 2 LIST OF ABBREVIATIONS ACR Acute Cellular Rejection AE Adverse Event AMR Antibody-Mediated Rejection ATG Anti-Thymocyte Globulin ATS American Thoracic Society BAL Bronchoalveolar Lavage BELA Belatacept BMS Bristol-Myers Squibb BOS Bronchiolitis Obliterans Syndrome CARV Community-Acquired Respiratory Virus/Viral CBC Complete Blood Counts CFR Code of Federal Regulations CIP Cellular Immunophenotyping CKD Chronic Kidney Disease CLAD Chronic Lung Allograft Dysfunction CMP Comprehensive Metabolic Panel CMV Cytomegalovirus CNI Calcineurin Inhibitor DCC Data Coordinating Center DSA Donor-Specific HLA Antibodies DSMB Data Safety and Monitoring Board EBV Epstein-Barr Virus ECLS Extra-Corporeal Life Support ECMO Extra-Corporeal Membrane Oxygenation FOB Fiberoptic Bronchoscopy GCP Good Clinical Practice HIV Human Immunodeficiency Virus HLA Human Leukocyte Antigens HSV Herpes Simplex Virus IgG Immunoglobulin G IP Investigational Product IRB Institutional Review Board IS Immunosuppression ISHLT International
    [Show full text]
  • Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York
    RAPID COMMUNICATION www.jasn.org Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York The Columbia University Kidney Transplant Program* Department of Medicine, Division of Nephrology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York ABSTRACT Background The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus kidney recipients (80%), with a me- disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be dian time since transplant of 49 at an increased risk of severe disease, little is known about their clinical presentation, (interquartile range, 38–118; range, disease course, or outcomes. 0–232) months (Table 1). All but one Methods We report 15 kidney transplant recipients from the Columbia University patientweretakingtacrolimusatthe kidney transplant program who required hospitalization for confirmed COVID-19, time of COVID-19 diagnosis, and and describe their management, clinical course, and outcomes. most (80%) were also taking either my- cophenolate mofetil or mycophenolic Results Patients presented most often with a fever (87%) and/or cough (67%). Initial acid. Despite our status as an early ste- chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute ra- roid withdrawal center for most trans- diographic findings. Patients were managed with immunosuppression reduction plants, ten patients (67%) were taking and the addition of hydroxychloroquine and azithromycin. Although 27% of our prednisone at the time of COVID-19 patients needed mechanical ventilation, over half were discharged home by the diagnosis. The underlying cause of end of follow-up. ESKD varied. Conclusions Kidney transplant recipients with COVID-19 have presentations that Patients reported symptom onset are similar to that of the general population.
    [Show full text]
  • Antibody-Mediated Rejection in Kidney Transplantation
    FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation The Choice of Induction / Maintenance Immunosuppression and their Impact on Preexisting and De Novo Antibodies Millie Samaniego, MD, FACP, FASN, FAST Alan B. Leichtman Collegiate Chair of Transplant Nephrology Professor of Medicine University of Michigan Disclosures • I have nothing to disclose in relation to this presentation: • Following drugs used “off label” will be discussed: • Thymoglobulin • Campath • IVIg • Belatacept • Rituximab • Eculizumab • C1q Inhibitors TABLE 1 The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients-A Systematic Review. Roberts, Darren; Jiang, Simon; Chadban, Steven Transplantation. 94(8):775-783, October 27, 2012. DOI: 10.1097/TP.0b013e31825d1587 TABLE 1 Therapeutic agents used against DSAs in the treatment of antibody- mediated rejection and the evidence supporting their role © 2012 Lippincott Williams & Wilkins, Inc. Published by Lippincott Williams & Wilkins, Inc. 2 FIGURE 2 The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients-A Systematic Review. Roberts, Darren; Jiang, Simon; Chadban, Steven Transplantation. 94(8):775-783, October 27, 2012. DOI: 10.1097/TP.0b013e31825d1587 FIGURE 2 . Trends in the use of treatments for AMR over time on the basis of all publications identified in the systematic review. Using a gray scale, black represents the most commonly used (in the case of PP, approximately 700 patients were treated between 2007 and 2011), whereas no color (white) means that it was not used. This includes patients from any observational, treatment, or epidemiology-based study identified in the systematic review. The use of tacrolimus and mycophenolate in patients with AMR is likely to be underrepresented in this figure because in recent years, these treatments are commonly used as baseline immunosuppression for high-risk KTRs, whereas the data included here only included new treatments administered to patients in response to a diagnosis of AMR/vascular rejection.
    [Show full text]
  • Lessons Learned: Early Termination of A
    Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept Kenneth Newell, Emory University Aneesh Mehta, Emory University Christian Larsen, Emory University Peter G. Stock, University of California San Francisco Alton B Farris III, Emory University Shikha G. Mehta, University of Alabama Birmingham David Ikle, Rho Inc. Brian Armstrong, Rho Inc. Yvonne Morrison, National Institute of Allergy and Infectious Diseases Nancy Bridges, National Institute of Allergy and Infectious Diseases Only first 10 authors above; see publication for full author list. Journal Title: American Journal of Transplantation Volume: Volume 17, Number 10 Publisher: Wiley: 12 months | 2017-10-01, Pages 2712-2719 Type of Work: Article | Post-print: After Peer Review Publisher DOI: 10.1111/ajt.14377 Permanent URL: https://pid.emory.edu/ark:/25593/tdqdg Final published version: http://dx.doi.org/10.1111/ajt.14377 Copyright information: © 2017 The American Society of Transplantation and the American Society of Transplant Surgeons Accessed September 30, 2021 12:24 PM EDT HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Am J Transplant Manuscript Author . Author Manuscript Author manuscript; available in PMC 2018 October 01. Published in final edited form as: Am J Transplant. 2017 October ; 17(10): 2712–2719. doi:10.1111/ajt.14377. Lessons learned: Early termination of a randomized trial of calcineurin inhibitor and corticosteroid avoidance using Belatacept Kenneth A. Newell1,
    [Show full text]
  • Download (PDF)
    Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Information for the public Published: TBC nice.org.uk What has NICE said? Abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) are recommended as possible treatments for people with polyarticular juvenile idiopathic arthritis. Adalimumab and etanercept are recommended as possible treatments for people with enthesitis- related juvenile idiopathic arthritis. Etanercept is recommended as a possible treatment for people with psoriatic juvenile idiopathic arthritis. What does this mean? If your (or your child's) doctor thinks that abatacept, adalimumab, etanercept or tocilizumab are the right treatment, you (or your child) should be able to have the treatment on the NHS. Abatacept, adalimumab, etanercept and tocilizumab should be available on the NHS within 3 months of the guidance being issued. If you (or your child) are not eligible for treatment as described above, you (or your child) should be able to continue taking abatacept, adalimumab, etanercept or tocilizumab until you and your (or your child's) doctor decide it is the right time to stop. © NICE TBC. All rights reserved. Page 1 of 3 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Why has NICE said this? NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS. Abatacept, adalimumab, etanercept and tocilizumab were recommended because the benefits to patients justify their cost. The condition and the treatments Arthritis causes pain and inflammation in joints. Juvenile idiopathic arthritis is a type of arthritis that starts in people younger than 16 years (juvenile).
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Table S1. Medications Searched in Institutional Database Query Immune Checkpoint Inhibitors Additional Immune Modulators Atezol
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Table S1. Medications Searched in Institutional Database Query Immune Checkpoint Inhibitors Additional Immune Modulators Atezolizumab Abatacept Avelumab Adalimumab Cemiplimab Anakinra Durvalumab Belatacept Ipilimumab Certolizumab Lirilumab Cyclophosphamide Mogamulizumab Etanercept Nivolumab Golimumab Pembrolizumab Immune globulin IV Tremelimumab Infliximab Urelumab Mycophenolate mofetil Varlilumab Rituximab Tocilizumab Vedolizumab Beattie J, et al. J Immunother Cancer 2021; 9:e001884. doi: 10.1136/jitc-2020-001884 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Table S2. Toxicity of additional immune modulators Treatment detail Toxicity Patient 1 day 18,32 Infliximab dosed day 59 P.aeruginosa, S.marcescens pneumonia; died Patient 2 day 9 Infliximab dosed day 44 Febrile neutropenia; P. aeruginosa SBP and day 26 Mycophenolate initiated sepsis; C. albicans fungemia; treated and discharged Patient 8 day 4,11 Infliximab dosed day 14 Disseminated HSV-1; died Patient 26 day 79-128 Infliximab dosed (x7) day 130 E. faecalis, P. aeruginosa bacteremia; died; day 81, 97 Cyclophosphamide dosed Fungal pneumonia on autopsy Beattie J, et al. J Immunother Cancer 2021; 9:e001884. doi: 10.1136/jitc-2020-001884 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Table S3.
    [Show full text]
  • Re-Treatment with Abatacept Plus Methotrexate for Disease Flare After Complete Treatment Withdrawal in Patients with Early Rheum
    Rheumatoid arthritis RMD Open: first published as 10.1136/rmdopen-2018-000840 on 8 February 2019. Downloaded from ORIGINAL ARTICLE Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study Paul Emery,1,2 Gerd R Burmester,3 Vivian P Bykerk,4 Bernard G Combe,5 Daniel E Furst,6 Michael A Maldonado,7 Tom WJ Huizinga8 To cite: Emery P, Burmester GR, ABSTRACT Bykerk VP, et al. Re- Objectives To complete reporting of outcomes after total Key messages treatment with abatacept withdrawal of all rheumatoid arthritis (RA) therapy and re- plus methotrexate for disease treatment after flare inA ssessing Very Early Rheumatoid What is already known about this subject? flare after complete treatment arthritis Treatment study (NCT01142726). ► Abatacept in combination with methotrexate induc- withdrawal in patients with es remission more often than methotrexate alone early rheumatoid arthritis: Methods Patients with early RA were initially randomised to double-blind, weekly subcutaneous abatacept plus after 12 months of treatment, with a greater propor- 2-year results from the tion of patients with rheumatoid arthritis (RA) main- AVERT study. methotrexate, or abatacept or methotrexate monotherapy. RMD Open taining remission over 6 months following treatment 2019;5:e000840. doi:10.1136/ At month 12, patients with Disease Activity Score (DAS)28 rmdopen-2018-000840 C reactive protein (CRP) <3.2 had all RA treatments rapidly withdrawal. withdrawn and were observed for ≤12 months or until What does this study add? flare.A fter ≥3 months’ withdrawal, patients with protocol- ► Prepublication history and ► These final results of theA ssessing Very Early additional material for this defined RA flare received open-label abatacept plus Rheumatoid arthritis Treatment (AVERT) study paper are available in online.
    [Show full text]